Company
ASX:RCE
Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
169 stories · page 8 of 9
“Completing this Cohort with the maximum number of subjects, sees R327 (500mg, I.V.) further a compelling Safety profile at a milestone dose. We anticipate recommendation to start dosing Cohort 4 at higher concentrations again in near weeks
According to PEW Charitable Trusts global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
According to PEW Charitable Trusts global antibiotic pipeline review, RECCE 327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
According to PEW Charitable Trust, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
R327 is administered as a single dose via a 1-hour IV infusion at a uniform rate, with all 80 subjects anticipated to have been dosed by the end of H1 2022.
Speculation has been rife over what caused the flash crash, with some analysts citing the expiry of leveraged positions. Other evidence meanwhile points to significantly increased activity with investors moving crypto assets from wallets to
“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic," says CEO.
In March this year, Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Receiving human ethics approval is a momentous achievement for Recce and the clinicians seeking effective treatments to combat antibiotic-resistant bacteria,” says chairman.
RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours, at varying concentrations.
Following encouraging test results from stage1A and stage1B, RECCE® R327 received a qualified recommendation to advance to stage 2 of the program for further testing to be conducted by CSIRO.
The company is pioneering the development and commercialisation of new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.
Five companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.
The company is pioneering the development of a new class of synthetic antibiotics with broad-spectrum activity, designed to address the problem of antibiotic superbugs.
The company’s lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria.
Overseas Advanced Drug Development expenditure for RECCE® 327 results in extra payment of $861,590.
James Graham will discuss with investors the next key steps.
Greg Cochran will discuss with investors the next key steps.
The halt will remain in place until Thursday 16th November 2017.
Recce 327 is a synthetic compound being developed to fight against superbugs.
